Search results
Results from the WOW.Com Content Network
Interferon beta-1b is a cytokine in the interferon family used to treat the relapsing-remitting and secondary-progressive forms of multiple sclerosis (MS). It is approved for use after the first MS event.
Unfortunately, the resultant protein did not live up to its expectations as a broad-spectrum anti-cancer drug, and only much later was it approved for use to treat symptoms of multiple sclerosis. [2] The product is now sold under the name Betaseron. The company's flagship product was Interleukin-2 (IL-2), an important modifier of the immune system.
This was followed a year later by Betaseron, a beta interferon, the first treatment for relapsing-remitting multiple sclerosis and made by Berlex Laboratories Inc. [22] [23] In 1997 Chiron provided the active ingredient, becaplermin, in Regranex, a topical treatment for diabetic foot ulcers, manufactured by Ortho-McNeil Pharmaceutical Inc. [24 ...
For premium support please call: 800-290-4726 more ways to reach us
Here is the list in order of FDA approval date. Read On The Fox News App. 1. Dupixent – Additional use: Eosinophilic esophagitis (an allergic condition that causes inflammation of the esophagus) 2.
Interferon beta-1a (also interferon beta 1-alpha) is a cytokine in the interferon family used to treat multiple sclerosis (MS). [5] It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. [6]
One was first approved for medical use in 1986. [59] For example, in January 2001, the Food and Drug Administration (FDA) approved the use of PEGylated interferon-alpha in the USA; in this formulation, PEGylated interferon-alpha-2b ( Pegintron ), polyethylene glycol is linked to the interferon molecule to make the interferon last longer in the ...
Rank Brand Name(s) Generic Name Sales Q1 2014 Sales ($000) Change from Q4 2013 Company(ies) Disease/Medical Use First Approval Date Patent Expiration Date [6] [7]; 1: Abilify